Addressing the "Fas counterattack" controversy: Blocking fas ligand expression suppresses tumor immune evasion of colon cancer in vivo

Cancer Research

Volumn 65, Issue 21, 2005, Pages 9817-9823

  Ryan, Aideen E ^a   Shanahan, Fergus ^a,b   O'Connell, Joe ^a,b   Houston, Aileen M ^a,b  

^a University College Cork and INFANT Centre   (Ireland)

^b UNIVERSITY COLLEGE CORK   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; FAS ANTIGEN; FAS LIGAND; GENOMIC DNA; MEMBRANE PROTEIN; TUMOR NECROSIS FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL ASSAY; CELL DEATH; CELL PROLIFERATION; COLON CARCINOGENESIS; COLON CARCINOMA; CONTROLLED STUDY; DOWN REGULATION; EFFECTOR CELL; FEMALE; FLOW CYTOMETRY; GENETIC TRANSFECTION; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IMMUNOLOGICAL TOLERANCE; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTIC INFILTRATION; MOUSE; MOUSE STRAIN; NEUTROPHIL; NONHUMAN; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROVOCATION TEST; TUMOR ESCAPE; TUMOR GROWTH; TUMOR IMMUNITY; TUMOR VOLUME;

ANIMALS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; COLONIC NEOPLASMS; DNA, ANTISENSE; DOWN-REGULATION; FAS LIGAND PROTEIN; FEMALE; LYMPHOCYTES, TUMOR-INFILTRATING; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED C57BL; NEOPLASM TRANSPLANTATION; NEUTROPHILS; RNA, ANTISENSE; TRANSFECTION; TUMOR NECROSIS FACTORS;

EID: 27544457676     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-1462     Document Type: Article

References (48)

1. Ahmad M, Rees RC, Ali SA. Escape from immunotherapy: possible mechanisms that influence tumor regression/progression. Cancer Immunol Immunother 2004;53:844-54. Epub 2004 Jun 10.
2. Suda T, Takahashi T, Golstein P, Nagata S. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 1993; 75:1169-78.
3. Nagata S, Golstein P. The Fas death factor. Science 1995;267:1449-56.
4. Brunner T, Wasem C, Torgler R, Cima I, Jakob S, Corazza N. Fas (CD95/Apo-1) ligand regulation in T cell homeostasis, cell-mediated cytotoxicity and immune pathology. Semin Immunol 2003;15:167-76.
5. Griffith TS, Brunner T, Fletcher SM, Green DR, Ferguson TA. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science 1995;270: 1189-92.
6. Bellgrau D, Gold D, Selawry H, Moore J, Franzusoff A, Duke RC. A role for CD95 ligand in preventing graft rejection. Nature 1995;377:630-2.
7. O'Connell J, O'Sullivan GC, Collins JK, Shanahan F. The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J Exp Med 1996;184: 1075-82.
8. Niehans GA, Brunner T, Frizelle SP, et al. Human lung carcinomas express Fas ligand. Cancer Res 1997;57: 1007-12.
9. Song E, Chen J, Ouyang N, Su F, Wang M, Heemann U. Soluble Fas ligand released by colon adenocarcinoma cells induces host lymphocyte apoptosis: an active mode of immune evasion in colon cancer. Br J Cancer 2001; 85:1047-54.
10. Krammer PH. CD95's deadly mission in the immune system. Nature 2000;407:789-95.
11. Bennett MW, O'Connell J, O'Sullivan GC, et al. The Fas counterattack in vivo: apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma. J Immunol 1998;160:5669-75.
12. Okada K, Komuta K, Hashimoto S, Matsuzaki S, Kanematsu T, Koji T. Frequency of apoptosis of tumor-infiltrating lymphocytes induced by fas counterattack in human colorectal carcinoma and its correlation with prognosis. Clin Cancer Res 2000;6:3560-4.
13. Chen CM, Song W, Kao JY, Zheng QD, Chen JJ. Expression of Fas ligand is not a main mechanism used by tumors to counteract antitumor immunity. Front Biosci 2004;9:448-56.
14. Kang SM, Schneider DB, Lin Z, et al. Fas ligand expression in islets of Langerhans does not confer immune privilege and instead targets them for rapid destruction. Nat Med 1997;3:738-43.
15. Takeuchi T, Ueki T, Nishimatsu H, et al. Accelerated rejection of Fas ligand-expressing heart grafts. J Immunol 1999;162:518-22.
16. Tourneur L, Malassagne B, Batteux F, et al. Transgenic expression of CD95 ligand on thyroid follicular cells confers immune privilege upon thyroid allografts. J Immunol 2001;167:1338-46.
17. Li XK, Okuyama T, Tamura A, et al. Prolonged survival of rat liver allografts transfected with Fas ligand-expressing plasmid. Transplantation 1998;66: 1416-23.
18. Cefai D, Favre L, Wattendorf E, Marti A, Jaggi R, Gimmi CD. Role of Fas ligand expression in promoting escape from immune rejection in a spontaneous tumor model. Int J Cancer 2001;91:529-37.
19. Batteux F, Lores P, Bucchini D, Chiocchia G. Transgenic expression of Fas ligand on thyroid follicular cells prevents autoimmune thyroiditis. J Immunol 2000; 164:1681-8.
20. Chervonsky AV, Wang Y, Wong FS, et al. The role of Fas in autoimmune diabetes. Cell 1997;89:17-24.
21. Hohlbaum AM, Moe S, Marshak-Rothstein A. Opposing effects of transmembrane and soluble Fas ligand expression on inflammation and tumor cell survival. J Exp Med 2000;191:1209-20.
22. Chen JJ, Sun Y, Nabel GJ. Regulation of the proinflammatory effects of Fas ligand (CD95L). Science 1998;282:1714-7.
23. Aubry JP, Blaecke A, Lecoanet-Henchoz S, et al. Annexin V used for measuring apoptosis in the early events of cellular cytotoxicity. Cytometry 1999;37: 197-204.
24. Freiberg RA, Spencer DM, Choate KA, et al. Fas signal transduction triggers either proliferation or apoptosis in human fibroblasts. J Invest Dermatol 1997;108: 215-9.
25. Desbarats J, Newell MK. Fas engagement accelerates liver regeneration after partial hepatectomy. Nat Med 2000;6:920-3.
26. Houston A, Bennett MW, O'Sullivan GC, Shanahan F, O'Connell J. Fas ligand mediates immune privilege and not inflammation in human colon cancer, irrespective of TGF-β expression. Br J Cancer 2003;89: 1345-51.
27. Reichert TE, Strauss L, Wagner EM, Gooding W, Whiteside TL. Signaling abnormalities, apoptosis, and reduced proliferation of circulating and tumor-infiltrating lymphocytes in patients with oral carcinoma. Clin Cancer Res 2002;8:3137-45.
28. Liles WC, Kiener PA, Ledbetter JA, Aruffo A, Klebanoff SJ. Differential expression of Fas (CD95) and Fas ligand on normal human phagocytes: implications for the regulation of apoptosis in neutrophils. J Exp Med 1996; 184:429-40.
29. Restifo NP. Not so Fas: re-evaluating the mechanisms of immune privilege and tumor escape. Nat Med 2000;6: 493-5.
30. O'Connell J, Houston A, Bennett MW, O'Sullivan GC, Shanahan F. Immune privilege or inflammation? Insights into the Fas ligand enigma. Nat Med 2001;7: 271-4.
31. Cardi G, Heaney JA, Schned AR, Ernstoff MS. Expression of Fas(APO-1/CD95) in tumor-infiltrating and peripheral blood lymphocytes in patients with renal cell carcinoma. Cancer Res 1998;58:2078-80.
32. O'Connell J, Bennett MW, O'Sullivan GC, et al. Fas ligand expression in primary colon adenocarcinomas: evidence that the Fas counterattack is a prevalent mechanism of immune evasion in human colon cancer. J Pathol 1998;186:240-6.
33. Gastman BR, Atarshi Y, Reichert TE, et al. Fas ligand is expressed on human squamous cell carcinomas of the head and neck, and it promotes apoptosis of T lymphocytes. Cancer Res 1999;59:5356-64.
34. Abrahams VM, Straszewski SL, Kamsteeg M, et al. Epithelial ovarian cancer cells secrete functional Fas ligand. Cancer Res 2003;63:5573-81.
35. Belluco C, Esposito G, Bertorelle R, et al. Fas ligand is up-regulated during the colorectal adenoma-carcinoma sequence. Eur J Surg Oncol 2002;28:120-5.
36. Kase H, Aoki Y, Tanaka K. Fas ligand expression in cervical adenocarcinoma. Relevance to lymph node metastasis and tumor progression. Gynecol Oncol 2003; 90:70-4.
37. Hahne M, Rimoldi D, Schroter M, et al. Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape. Science 1996;274:1363-6.
38. Khar A, Varalakshmi C, Pardhasaradhi BV, Mubarak Ali A, Kumari AL. Depletion of the natural killer cell population in the peritoneum by AK-5 tumor cells overexpressing fas-ligand: a mechanism of immune evasion. Cell Immunol 1998;189:85-91.
39. Arai H, Chan SY, Bishop DK, Nabel GJ. Inhibition of the alloantibody response by CD95 ligand. Nat Med 1997;3:843-8.
40. Cefai D, Schwaninger R, Balli M, Brunner T, Gimmi CD. Functional characterization of Fas ligand on tumor cells escaping active specific immunotherapy. Cell Death Differ 2001;8:687-95.
41. Ke B, Coito AJ, Kato H, et al. Fas ligand gene transfer prolongs rat renal allograft survival and down-regulates anti-apoptotic Bag-1 in parallel with enhanced Th2-type cytokine expression. Transplantation 2000;69: 1690-4.
42. Seino K, Kayagaki N, Okumura K, Yagita H. Antitumor effect of locally produced CD95 ligand. Nat Med 1997;3:165-70.
43. Abreu-Martin MT, Vidrich A, Lynch DH, Targan SR. Divergent induction of apoptosis and IL-8 secretion in HT-29 cells in response to TNF-α and ligation of Fas antigen. J Immunol 1995;155:4147-54.
44. Shimada M, Andoh A, Araki Y, Fujiyama Y, Bamba T. Ligation of the Fas antigen stimulates chemokine secretion in pancreatic cancer cell line PANC-1. J Gastroenterol Hepatol 2001;16:1060-7.
45. Mariani SM, Matiba B, Baumler C, Krammer PH. Regulation of cell surface APO-1/Fas (CD95) ligand expression by metalloproteases. Eur J Immunol 1995;25: 2303-7.
46. Hohlbaum AM, Gregory MS, Ju ST, Marshak-Rothstein A. Fas ligand engagement of resident peritoneal macrophages in vivo induces apoptosis and the production of neutrophil chemotactic factors. J Immunol 2001;167:6217-24.
47. Niederkorn JY. Mechanisms of immune privilege in the eye and hair follicle. J Investig Dermatol Symp Proc 2003;8:168-72.
48. Ferguson TA, Green DR. Fas-ligand and immune privilege: the eyes have it. Cell Death Differ 2001;8:771-2.